A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients
Tekijät: Babu, Ambrin Farizah; Palomurto, Saana; Kärjä, Vesa; Käkelä, Pirjo; Lehtonen, Marko; Hanhineva, Kati; Pihlajamäki, Jussi; Männistö, Ville
Kustantaja: Elsevier Inc.
Julkaisuvuosi: 2024
Journal: Digestive and Liver Disease
Tietokannassa oleva lehden nimi: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Lehden akronyymi: Dig Liver Dis
Vuosikerta: 56
Numero: 12
Aloitussivu: 2103
Lopetussivu: 2110
ISSN: 1590-8658
eISSN: 1878-3562
DOI: https://doi.org/10.1016/j.dld.2024.05.015
Verkko-osoite: https://doi.org/10.1016/j.dld.2024.05.015
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/454678670
Backround
Metabolic dysfunction-associated steatotic liver disease (MASLD) can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Still, most patients with MASLD die from cardiovascular diseases indicating metabolic alterations related to both liver and cardiovascular pathology.
Aims and Methods
The aim of this study was to assess biologic pathways behind MASLD progression from steatosis to metabolic dysfunction-associated steatohepatitis (MASH) using non-targeted liquid chromatography-mass spectrometry analysis in 106 severely obese individuals (78 women, mean age 47.7 7 ± 9.2 years, body mass index 41.8 ± 4.3 kg/m²) undergoing laparoscopic Roux-en-Y gastric bypass.
Results
We identified several metabolites that are associated with MASLD progression. Most importantly, we observed a decrease of lysophosphatidylcholines LPC(18:2), LPC(18:3), and LPC(20:3) and increase of xanthine when comparing those with steatosis to those with MASH. We found that indole propionic acid and threonine were negatively correlated to fibrosis, but not with the metabolic disturbances associated with cardiovascular risk. Xanthine, ketoleucine, and tryptophan were positively correlated to lobular inflammation and ballooning but also with insulin resistance, and dyslipidemia, respectively. The results did not change when taking into account the most important genetic risk factors of MASLD.
Conclusions
Our findings suggest that there are several separate biological pathways, some of them independent of insulin resistance and dyslipidemia, associating with MASLD.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
This work was supported by the ITN Marie Curie BestTreat-Building a Gut Microbiome Engineering Toolbox for In Situ Therapeutic Treatments for Non-alcoholic Fatty Liver Disease (grant number 813781, A.F.B). K.H. is supported by Research Council of Finland (grant no. 321716) and ERA-NET NEURON (grant no. 334814). Kuopio Obesity Surgery Study was supported by the Finnish Diabetes Research Foundation, Kuopio University Hospital Project grant (EVO/VTR grants 2005‐2021), the Academy of Finland grant (Contract no. 138006), the Finnish Cultural Foundation, and the University of Eastern Finland Spearhead Funding (J.P.). V.M. was supported by the Mary and Georg C. Ehrnrooth Foundation, Finnish Medical Foundation, Sigrid Jusélius Foundation, and Kuopio University Hospital Project grant (VTR grants).
